RASGRF2 and gastric adenocarcinoma: Findings of a ROC analysis suggested that RASGRF2 may have diagnostic value as a biomarker in the context of STAD, while findings of a Kaplan-Meier survival analysis in conjunction with a multivariate Cox regression model suggested that RASGRF2 may also have prognostic value (e.g. in predicting OS).